Phase II Randomized Trial of Biweekly Bevacizumab, Capecitabine, Oxaliplatin and Irinotecan (BEV- CAPEOXIRI) Versus Triweekly Bevacizumab, Capecitabine and Oxaliplatin (BEV- CAPEO - Egyptian Knowledge Bank

61489

Phase II Randomized Trial of Biweekly Bevacizumab, Capecitabine, Oxaliplatin and Irinotecan (BEV- CAPEOXIRI) Versus Triweekly Bevacizumab, Capecitabine and Oxaliplatin (BEV- CAPEO

Article

Last updated: 01 Jan 2025

Overview Similar Items

Article

Bevacizumab and weekly dose-dense paclitaxel and carboplatin in recurrent epithelial ovarian carcinoma: A phase II trial

Article

NEO-ADJUVANT VERSUS ADJUVANT USE OF BEVACIZUMAB IN THE MANAGEMENT OF ADVANCED OVARIAN CANCER

Article

Angiogenesis Versus Antiangiogenesis in Colorectal Cancer Patients with and Without Liver Metastases

Article

Modified-FOLFIRINOX-Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase II Study

Article

A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN trial)

Article

CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY)

Article

Standard versus Modified FOLFIRINOX Protocols in Patients with Metastatic Pancreatic Carcinoma: Efficacy versus Toxicity

Article

Anti-Epithelial Growth Factor Receptors for Prognosis in Management of Metastatic Colorectal Cancer

Article

Does the number of metastatic organ involvement affect the response to irinotecan-based chemotherapy in patients with metastatic colorectal

Article

Evaluation of The outcome and Toxicity in Patient with Colon Cancer Treated With chemotherapy (Retrospective Study)